Compare Angi Inc (ANGI) vs Johnson & Johnson (JNJ) Price & Performance

ANGI trades at $6.24, down 1.89% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue of $1.03B in 2025 and net income of $43.83M, representing a 4.25% margin. Valuation metrics appear attractive with P/E of 14.85 and P/S of 0.27. Recent earnings showed a beat in Q1 2026 but misses in previous quarters, while analyst consensus price target sits at $9.20 with 33% buy ratings.

The stock presents a mixed outlook with attractive valuation multiples offset by declining revenue trends and ongoing legal investigations. Upside potential exists if the company's AI transition strategy succeeds, but risks include deteriorating core business metrics and multiple fraud investigations that could pressure shareholder value in the near term.

Johnson & Johnson (JNJ) trades at $256.98, down 0.82% today, with a bullish technical signal from moving averages and a consensus analyst price target of $268.50. The company reported strong Q1 2026 EPS of $2.70, beating expectations, and maintains robust profitability with a net income margin of 21.83%. Recent news highlights dividend growth strategies and comparisons with peers like AbbVie, while cash flow trends show operational strength despite negative net cash flow in 2025.

JNJ presents a stable investment opportunity with consistent earnings beats and a solid dividend, but faces risks from rising debt levels and competitive pressures. The stock's current valuation metrics, including a P/E of 29.78, suggest it is fairly valued with moderate upside potential based on analyst targets. Investors should weigh the company's strong fundamentals against macroeconomic and sector-specific headwinds.